Adjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCC

Watchdoq June 2, 2025

(MedPage Today) -- CHICAGO -- Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients at high risk of recurrence of cutaneous squamous-cell carcinoma (SCC), a phase III randomized trial...

Read Full Article